Rabiya Tuma
Oncology and HCP Editorial Lead at HealthCentral Corporation
Oncology and HCP Editorial Lead at Oncology News Central
Oncology and HCP Editorial Lead at Patient Power
Oncology and HCP editorial lead @RemHealthMedia, @OBRtweets and @PatientPower. Science and medical writer, former bench scientist. Tweets are my own. She/her
Articles
-
May 7, 2024 |
oncologynewscentral.com | Leah Lawrence |Youssef Rddad |Rabiya Tuma |Ursula Matulonis
-
Apr 18, 2024 |
obroncology.com | Rabiya Tuma
On April 18, the U.S. Food and Drug Administration approved alectinib (Alecensa) for the treatment of adults with early-stage anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. The approval is based on results from the ALINA trial, which compared single-agent alectinib with platinum-based chemotherapy.
-
Mar 17, 2023 |
obroncology.com | Rabiya Tuma
-
Dec 12, 2022 |
obroncology.com | Ashley Taylor |Rabiya Tuma
-
Dec 10, 2022 |
obroncology.com | Rabiya Tuma
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 381
- Tweets
- 383
- DMs Open
- Yes
RT @OncBrothers: #WCLC24 ~5 wks away! Current SoC + how is the data from #WCLC24 @IASLC impact our clinical practice at Advancements in Onc…
RT @OncNewsCentral: "Medicine, and within that oncology, is an amazing career. But it can be totally encompassing at times. At the end of t…
RT @OncNewsCentral: ONC's Summer Reading List is curated by top cancer experts. Discover why their picks, from fiction to beyond medicine,…
